Allergy immunotherapy market seen reaching $5.64 billion by 2030

The allergy immunotherapy market is projected to grow from $3.55 billion in 2026 to $5.64 billion by 2030, driven by rising allergic disease rates, more personalized treatments and wider access through online channels. Europe leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Allergy immunotherapy is gaining traction as allergic conditions rise worldwide and more patients seek longer-term treatment options beyond traditional symptom relief. - The market’s growth points to rising demand for therapies targeting allergic rhinitis, asthma, food allergies and venom allergies. - The expansion also signals more investment in pediatric allergy care, research and combination therapies.

What happened: - The Business Research Company said the global allergy immunotherapy market is projected to rise from $3.55 billion in 2026 to $5.64 billion by 2030. - That forecast implies a 12.2% compound annual growth rate through 2030. - The company also said the market grew from $3.16 billion in 2025 to $3.55 billion in 2026, a 12.3% CAGR. - The report is titled Allergy Immunotherapy Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report includes market sizing, trends, regional outlook and future forecasts. - The company offers a free sample report and the full market report.

The details: - Allergy immunotherapy works by giving gradually increasing doses of allergens such as house dust mites, grass pollen or bee venom. - The treatment is designed to reduce sensitivity over time and lower the severity of allergic reactions. - Rising incidence of allergic disorders is a major growth driver. - Allergic disorders are triggered by environmental allergens such as pollen and dust mites. - The market is linked to IgE-mediated allergic rhinitis and allergic asthma caused by inhaled allergens. - Growth drivers cited for the forecast period include personalized immunotherapy, wider use of online pharmacy channels, growth in pediatric allergy care, increased research investment and combination immunotherapy products. - Key trends cited for the forecast period include broader use of subcutaneous and sublingual immunotherapy, higher prevalence of allergic rhinitis and asthma, advances in food and venom allergy treatments, stronger focus on personalized protocols and improved awareness and early diagnosis.

Between the lines: - The forecast suggests allergy care is shifting from broad, one-size-fits-all approaches toward more targeted and convenient treatment models. - Online pharmacy channels and personalized protocols point to a market that is moving closer to patients and becoming more tailored to specific allergy types. - The report’s emphasis on early diagnosis and awareness suggests untreated or undertreated allergies remain a major commercial and public health opportunity. - Europe held the largest market share in 2025, but Asia-Pacific is expected to post the fastest growth over the forecast period.

What’s next: - The market is expected to keep expanding through 2030 as demand grows for long-term allergy management. - More product development is likely around subcutaneous and sublingual options, pediatric care and combination therapies. - The report also expands its strategic intelligence tools, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards and hotspot infographics. - The company lists regional contact information for expert inquiries and says the report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - Allergy immunotherapy is moving from a niche treatment category into a faster-growing global market shaped by rising allergy rates, broader access and more personalized care.